Source: Health Canada shortage reports · Updated Jul 22, 2026
Some Sunitinib products are in shortage in Canada (2 of 9 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Aug 31, 2026.
A tyrosine kinase inhibitor used to treat certain cancers, including kidney cancer.
Products affected
2 / 9
In shortage since
Apr 13, 2026
Est. full return
Aug 31, 2026
Reports on file
12
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
SUTENT
25MG · CAPSULE · PFIZER CANADA ULC
DIN 02280809 · since Jul 14, 2026, est. end Aug 31, 2026 · Demand increase for the drug.
Active shortage
NAT-SUNITINIB
12.5MG · CAPSULE · NATCO PHARMA (CANADA) INC
DIN 02552892 · since Apr 13, 2026, est. end Aug 31, 2026 · Disruption of the manufacture of the drug.
Resolved
TARO-SUNITINIB
25MG · CAPSULE · TARO PHARMACEUTICALS INC
DIN 02524066 · ended Jun 16, 2025 · Disruption of the manufacture of the drug.
Resolved
SANDOZ SUNITINIB
50MG · CAPSULE · SANDOZ CANADA INCORPORATED
DIN 02532883 · ended Feb 17, 2025 · Delay in shipping of the drug.
Resolved
SANDOZ SUNITINIB
25MG · CAPSULE · SANDOZ CANADA INCORPORATED
DIN 02532867 · ended Feb 17, 2025 · Delay in shipping of the drug.
Resolved
SANDOZ SUNITINIB
12.5MG · CAPSULE · SANDOZ CANADA INCORPORATED
DIN 02532840 · ended Feb 17, 2025 · Delay in shipping of the drug.
Resolved
TARO-SUNITINIB
12.5MG · CAPSULE · TARO PHARMACEUTICALS INC
DIN 02524058 · ended Nov 8, 2024 · Disruption of the manufacture of the drug.
Resolved
TARO-SUNITINIB
50MG · CAPSULE · TARO PHARMACEUTICALS INC
DIN 02524082 · ended Jan 10, 2023 · Shortage of an active ingredient.
Resolved
TARO-SUNITINIB
50MG · CAPSULE · TARO PHARMACEUTICALS INC
DIN 02524082 · ended Jan 10, 2023 · Shortage of an active ingredient.
Resolved
TARO-SUNITINIB
25MG · CAPSULE · TARO PHARMACEUTICALS INC
DIN 02524066 · ended Nov 30, 2022 · Shortage of an active ingredient.
Resolved
TARO-SUNITINIB
25MG · CAPSULE · TARO PHARMACEUTICALS INC
DIN 02524066 · ended Nov 30, 2022 · Shortage of an active ingredient.
Resolved
SUTENT
50MG · CAPSULE · PFIZER CANADA ULC
DIN 02280817 · ended Jun 7, 2022 · Demand increase for the drug.
What's happening
Sunitinib is currently affected by 2 active shortage reports filed with Health Canada by PFIZER CANADA ULC, NATCO PHARMA (CANADA) INC.
The reported causes are: demand increase for the drug; disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Recent changes
Jul 22, 2026
Status changed
Jul 22, 2026
Estimated end date pushed back : Jul 15, 2026 → Aug 31, 2026
Common questions
What is Sunitinib used for?
A tyrosine kinase inhibitor used to treat certain cancers, including kidney cancer.
When will Sunitinib be back in stock in Canada?
The latest manufacturer estimate is Aug 31, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Sunitinib in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Possible alternatives in the same class
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.